Alex Szidon, PhD
VICE PRESIDENT, HEAD OF BUSINESS DEVELOPMENT FOR GRED, PHARMA PARTNERING, GENENTECH, A MEMBER OF THE ROCHE GROUP
South San Francisco, California, United States
As Vice President, Head of Business Development for gRED (Genentech Research and Early Development), Alex works with gRED leadership on business development strategies and is accountable for Search and Evaluation and leading partnering transactions in support of gRED's portfolio. Alex joined Genentech from Merck’s Pacific Business Development and Licensing Team accessing innovation throughout Asia, the western U.S. and Canada. In that role, Alex and his team augmented Merck’s pipeline through acquisitions and collaborations with biotechnology companies focusing on developing new modalities for therapy, new technologies for characterizing disease or patient response to therapy and new protein engineering platforms to increase the precision of treatment. Earlier in his career, Alex was a co-founder of Zafgen and DARA Biosciences, served as Director of BD, Office of Technology Development at the Harvard Medical School. Alex received his Ph.D. from UCSF in cell biology and biochemistry.
2:00 PM - 2:45 PM (EDT)
Tuesday, June 15
Delivering new and innovative products to market is necessary for the biopharma industry to grow…